BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. The company's two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. Source
No articles found.
Ansell Limited provides health and safety protection solutions. The Company has op...
Ansell Limited provides health and safety prote...
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat...
BioCryst Pharmaceuticals discovers novel, oral ...
At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients w...
At ACADIA (NASDAQ: ACAD), we share a passion fo...
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical...
Neurocrine Biosciences (Nasdaq: NBIX) is a neur...
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers...
At Biogen, our mission is clear: we are pioneer...
We are developing nalbuphine ER to treat serious neurologically mediated condition...
We are developing nalbuphine ER to treat seriou...
We are a biopharmaceutical company dedicated to the development of programmed cell...
We are a biopharmaceutical company dedicated to...
Join the National Investor Network and get the latest information with your interests in mind.